Opinions
The Monthly Gems by Allan Tong
Moderna
MRNA-Q
TOP PICK
May 11, 2020
There are general concerns that any pharma company can mass-supply its vaccine, but Moderna vows to begin its still-unapproved vaccine “as early as July.” Moderna is partnering with Swiss drugmaker, Lonza, to accelerate production on mRNA-1273, which was the first candidate to enter a phase 1 human trial back in March, though results are pending. A week ago, Moderna submitted an application to the FDA to start a phase 2 trial. The company says phase 3 could happen as soon as the fall. Moderna is developing mRNA-1273 with partner NIH (the National Institutes of Health). The federal NIH explains that the partners developed a candidate early, because they were already researching “related coronaviruses” together.
Unlike JNJ and Pfizer, Moderna's sole focus is vaccines to battle infectious diseases. Unlike those peers, Moderna did not suffer much of a plunge during the March bottom, and is currently trading at highs around $50. It pays no dividend and has an EPS of -1.55x and revenue growth of -55.42%. While JNJ and Pfizer can thrive if they don't find the vaccine, Moderna would have more to lose and the most to gain for this breakthrough.
$66.900
Stock price when the opinion was issued
Pharma & Healthcare
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
DON'T BUY